Trident Lifeline Limited Q2 Revenue Rises 50% to ₹47.1 Crore

Trident Lifeline Limited reported consolidated revenue of ₹47.08 crore for Q2 FY27, up 50.22% year-on-year from ₹31.34 crore, while consolidated profit after tax rose 29.67% to ₹6.60 crore for the quarter ended September 30, 2026. The results point to higher business activity across the company and its subsidiaries.

What did Trident Lifeline Limited report for Q2 FY27?

Trident Lifeline Limited, referred to as TLL, reported consolidated revenue from operations of ₹47.08 crore in Q2 FY27, compared with ₹31.34 crore in Q2 FY26. The company’s consolidated profit after tax increased to ₹6.60 crore from ₹5.09 crore in the corresponding quarter a year earlier.

The quarterly results cover the July to September 2026 period and were announced on October 26, 2026. TLL also reported operating profit of ₹7.84 crore, up 58.06% year-on-year from ₹4.96 crore. In its earnings summary, the company reported consolidated EBITDA of ₹11.3 crore, representing 65% year-on-year growth.

Standalone operations also recorded growth during the quarter. Standalone revenue rose 19.3% year-on-year to ₹32.7 crore, while standalone profit after tax increased 33.1% to ₹6.6 crore. The difference between standalone and consolidated revenue reflects the contribution of subsidiaries to the group’s reported operations.

Which figures were reported in the Q2 FY27 filing?

The reported figures show that revenue growth outpaced growth in profit after tax during Q2 FY27. Revenue increased by ₹15.74 crore year-on-year, while consolidated profit after tax increased by ₹1.51 crore. All figures below are presented on a consolidated basis and use ₹ crore as the common unit.

For the half year ended September 30, 2026, TLL reported consolidated revenue from operations of ₹80.80 crore and consolidated total income of ₹82.34 crore. Consolidated profit after minority interest for the six-month period stood at ₹11.63 crore, while consolidated basic and diluted earnings per share were ₹9.72.

The company reported standalone revenue from operations of ₹59.57 crore and standalone total income of ₹61.03 crore for the half year. Standalone net profit was ₹11.60 crore, with basic and diluted earnings per share of ₹9.70.

What business developments accompanied the quarterly results?

TLL said the quarterly performance reflected progress in product registrations, expansion into markets and contributions from subsidiaries. The company also cited capacity utilisation as part of its operating update, although the filing did not provide capacity utilisation percentages.

Management stated that a new parenterals facility was expected to be commissioned after Diwali. Parenterals are sterile medicines administered through routes other than the digestive tract, and the planned facility is therefore relevant to the company’s manufacturing expansion. TLL did not disclose the facility’s capacity, commissioning cost or expected revenue contribution in the supplied material.

The company also announced a proposed preferential issue intended to strengthen financial resources for strategic growth. No issue size, pricing, investor list or timeline was stated in the available information. A preferential issue typically involves the allotment of securities to selected investors, subject to applicable approvals and regulatory requirements.

Why were the half-year results revised and what remained unchanged?

TLL resubmitted revised standalone and consolidated financial statements for Q2 and the half year on October 27, 2026. It subsequently issued a revised financial result for the half year ended September 30, 2026 on November 4, 2026.

According to the announcement, the revisions involved regrouping of schedules and the totals remained unchanged. This means the reported headline financial amounts, including revenue and profit, were not altered by the revision. Investors examining the results should therefore distinguish between a presentation-related revision and a change in the underlying reported totals.

The company’s resource section lists annual reports for FY2023 through FY2026 and includes quarterly results, presentations and other investor documents. The available presentation dates include July 30 and November 13 for FY2025, and January 20, May 9 and August 3 for FY2026, as listed in the supplied material.

How do these results affect investors and TLL's operating plans?

For investors, the principal reported change is the increase in consolidated revenue to ₹47.08 crore and profit after tax to ₹6.60 crore in Q2 FY27. The rise in revenue was supported by a larger consolidated business base than standalone operations, indicating that subsidiary contributions were material to the group result.

The planned parenterals commissioning and proposed preferential issue are the main disclosed strategic items alongside the earnings release. Their financial effect cannot be quantified from the information available because TLL has not provided project capacity, capital expenditure, issue terms or a definitive implementation schedule.

TLL has stated an ambition to triple its consolidated business over the next three years through scaling of verticals and disciplined capital allocation. This is a management target rather than a reported financial result. Progress towards it will depend on execution across registrations, market expansion, capacity utilisation and the proposed capital actions.

Conclusion

TLL’s Q2 FY27 results showed a 50.22% year-on-year increase in consolidated revenue to ₹47.08 crore and a 29.67% increase in profit after tax to ₹6.60 crore. The half-year figures of ₹80.80 crore in consolidated revenue and ₹11.63 crore in profit after minority interest provide the broader context for the September-quarter performance.

The next disclosed matters to watch are the expected post-Diwali commissioning of the parenterals facility and further details of the proposed preferential issue. Investors can also track future filings for progress against TLL’s stated objective of tripling its consolidated business over the next three years.